Welcome to our dedicated page for Alto Neuroscienc news (Ticker: ANRO), a resource for investors and traders seeking the latest updates and insights on Alto Neuroscienc stock.
Alto Neuroscience Inc. (NYSE: ANRO) is a clinical-stage biopharmaceutical company developing precision medicines for neuropsychiatric disorders, and the ANRO news page on Stock Titan aggregates company-specific updates and disclosures. Alto regularly issues press releases on its clinical programs, biomarker research, regulatory designations, and financing activities, providing investors and observers with insight into its progress in precision psychiatry.
News coverage for Alto commonly includes clinical trial milestones for product candidates such as ALTO-207, ALTO-101, ALTO-100, ALTO-300, and ALTO-203. These updates may describe outcomes of FDA meetings, initiation or advancement of Phase 2 and Phase 3 studies, pharmacokinetic analyses, and proof-of-concept data in areas like treatment-resistant depression, bipolar depression, major depressive disorder, and cognitive impairment associated with schizophrenia. Alto also reports on validation of EEG biomarkers, including theta-band inter-trial coherence, and their use as primary outcomes in ongoing studies.
In addition to clinical data, Alto’s news releases cover regulatory and intellectual property developments, such as Fast Track designation for ALTO-101 in CIAS and the issuance of U.S. patents related to ALTO-207. Corporate and capital markets updates, including private placement financings, option repricings, board appointments, and inducement equity grants under NYSE rules, are also disclosed through company news.
This ANRO news feed allows readers to follow Alto Neuroscience’s reported developments in real time, from scientific presentations at conferences to investor events and SEC-related announcements. Users interested in biotechnology, neuropsychiatric drug development, and biomarker-driven clinical research can review these items to understand how Alto communicates its pipeline evolution and corporate actions.
Alto Neuroscience (NYSE: ANRO), a clinical-stage biopharmaceutical company developing precision medicines for neuropsychiatric disorders, has announced its participation in two major investor conferences in June 2025. The company will present at the Jefferies Global Healthcare Conference (June 3-5) in New York, featuring a fireside chat on June 5 at 2:00 pm ET. Additionally, Alto will participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference (June 16-17) with an on-demand presentation available from June 17 at 7:00 am ET. Both events will include one-on-one investor meetings, and presentations will be accessible via webcast on Alto's website.
Alto Neuroscience (NYSE: ANRO) presented significant findings at the Society of Biological Psychiatry Annual Meeting 2025, highlighting advancements in their precision psychiatry pipeline. The company successfully identified and validated an EEG-based biomarker for predicting placebo response in major depressive disorder (MDD) patients, potentially improving clinical trial efficiency.
Key developments include:
- Validation of EEG biomarker's ability to predict placebo response in MDD trials, with significant correlations in ALTO-100 Phase 2b and EMBARC sertraline trials
- New mechanistic insights linking ALTO-300's action to EEG biomarker patterns through 5-HT2C antagonism and dopamine regulation
- Positive results from ALTO-101's preclinical rescue study, demonstrating its potential for treating cognitive impairment in schizophrenia
- ALTO-203 showed promise in reversing anhedonia-like behavior in preclinical studies
Alto Neuroscience (NYSE: ANRO), a clinical-stage biopharmaceutical company developing precision medicines for neuropsychiatric disorders, has announced its participation in the upcoming JonesResearch Virtual CNS Day.
The company's management team will deliver a presentation on Tuesday, April 29, 2025, at 12:30 pm ET and engage in one-on-one investor meetings. Interested parties can access the presentation through a live webcast available on the Events and Presentations page in the Investors section of Alto's website, with a replay option available after the event.
Alto Neuroscience (NYSE: ANRO) reported its full-year 2024 financial results and pipeline updates. The company ended 2024 with a strong cash position of $169 million, expected to fund operations into 2028. Key financial metrics include R&D expenses of $47.0 million, G&A expenses of $21.6 million, and a net loss of $61.4 million.
Pipeline highlights include:
- ALTO-300: Favorable interim analysis in Phase 2b MDD trial with topline results expected mid-2026
- ALTO-203: Completed enrollment in Phase 2 MDD trial with data expected Q2 2025
- ALTO-101: New transdermal formulation showing improved drug exposure; Phase 2 schizophrenia trial data expected H2 2025
- ALTO-100: Ongoing Phase 2b trial in bipolar depression with data expected H2 2026
The company strengthened its patent portfolio with new grants covering ALTO-300 and ALTO-100 in biomarker-defined populations, extending protection until 2044 and 2043 respectively.
High-Trend International Group (NASDAQ: HTCO) has announced significant leadership changes, appointing Christopher Nixon Cox as Chairman and Bo Cui as Chief Legal Officer. Cox, who replaces Jinyu Chang (who remains a director), brings extensive experience in global markets and sustainability. He currently serves as CEO of Lightswitch Capital, Argali Carbon , and BioSource Feed , with previous roles including Vice Chairman of Brightsphere, Inc.
Cox's appointment aims to drive HTCO's strategic growth in innovation-driven sectors, particularly focusing on maritime low-carbon initiatives and ocean-based decarbonization. Bo Cui joins with over 20 years of experience in cross-border finance and M&A, having previously led $10 billion in strategic deals at HNA Group.
CEO Shixuan He emphasized that Cox's expertise in capital markets and green technologies aligns with the company's vision, while Cui's background in law and emerging technologies will strengthen their legal strategy and risk management during global expansion.
Alto Neuroscience (NYSE: ANRO), a clinical-stage biopharmaceutical company developing precision medicines for neuropsychiatric disorders, has announced its participation in three upcoming investor conferences in March 2025:
1. TD Cowen 45th Annual Health Care Conference (March 3-5, 2025)
- Presentation: Tuesday, March 4, 2025, at 9:50 am ET
- Location: Marriott Copley Place, Boston, MA
2. Leerink's Global Healthcare Conference 2025 (March 10-12, 2025)
- Presentation: Wednesday, March 12, 2025, at 8:00 am ET
- Location: W South Beach, Miami, FL
3. Stifel 2025 Virtual CNS Forum (March 18-19, 2025)
- Presentation: Tuesday, March 18, 2025, at 1:00 pm ET
All available presentations will be accessible via live webcast on the Events and Presentations page in the Investors section of Alto's website, with replays available following each presentation.
Alto Neuroscience (NYSE: ANRO) has been granted U.S. Patent Number 12,226,375 for its precision medicine approach in treating Major Depressive Disorder (MDD). The patent covers the use of ALTO-300 (agomelatine) as an adjunctive therapy for patients who have shown inadequate response to antidepressants, specifically using electroencephalogram (EEG) measures for patient selection.
ALTO-300 is an oral, small molecule designed to function as a melatonin agonist and 5-HT2C antagonist. The patent protection extends until 2044, not accounting for potential extensions. The treatment is being developed as an adjunctive therapy for biomarker-characterized MDD patients in the United States who haven't responded adequately to standard antidepressant treatments.